Professur für Rheumatologie und Klinische Immunologie

Rheumatologische Weiterbildungsstellen in Deutschland (2022) Pfeil A, Krusche M, Proft F, Vossen D, Braun J, Baraliakos X, Berliner MN, et al. Journal article Re-exposure with a TNF inhibitor bio-similar was well tolerated and led to sustained control of psoriatic arthritis after allergic reaction to the TNF inhibitor bio-originator (2022) Valor-Mendez L, Dorn C, Manger B, Schett G, Kleyer A Journal article, Letter Pseudoacrocyanosis: a case for telemedicine in rheumatology (2022) Manger B, Manger K Journal article Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis-A case report and literature review (2022) Yalcin Mutlu M, Taubmann J, Wacker J, Tascilar K, Fagni F, Gerner M, Klett D, et al. Journal article Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance (2022) Yalcin Mutlu M, Wacker J, Tascilar K, Taubmann J, Manger B, Krönke G, Schett G, Simon D Journal article, Letter Clinical Images: Tissue remodeling in autoimmune statin-induced necrotizing autoimmune myopathy (2022) Valor-Mendez L, Manger B, Knitza J, Schmidkonz C, Kleyer A, Schett G Journal article, Editorial Clinical Images: Voriconazole-induced synovitis, enthesitis, and periostitis (2022) Valor-Méndez L, Wacker J, Schett G, Manger B, Fürst J, Strauss R, Kleyer A Journal article CHARACTERIZATION OF RELAPSES IN PATIENTS WITH GIANT CELL ARTERITIS (GCA) PATIENTS- DATA FROM THE REAL-LIFE TREATMENT AND SAFETY (REATS)-GCA COHORT (2022) Schönau V, Corte G, Ott S, Tascilar K, Hartmann F, Manger B, Hellmich B, et al. Conference contribution LONG-TERM HUMORAL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASE (2022) Tascilar K, Simon D, Kleyer A, Fagni F, Krönke G, Meder C, Dietrich P, et al. Conference contribution PRE-EXPOSURE PROPHYLAXIS FOR SARS-COV-2 INFECTION WITH SUBCUTANEOUS CASIRIVIMAB/IMDEVIMAB IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES. (2022) Fagni F, Schmidt K, Bohr D, Valor L, Hartmann F, Tascilar K, Manger K, et al. Conference contribution